other material
confidence high
sentiment positive
materiality 0.65
Bicara reports 57% ORR in Phase 1b expansion; deeper responses at 1500mg dose; dose declaration on track for Q1 2026
Bicara Therapeutics Inc.
- 750mg ficerafusp alfa + pembrolizumab showed 57% confirmed ORR (17/30) with 10% complete response.
- At 1500mg, median depth of response was 82% vs 63% at 750mg at 24 weeks.
- Deep response rate (≥80% shrinkage) was 64% at 1500mg vs 27% at 750mg.
- Safety profile consistent with known safety; no new tolerability concerns.
- Company on track to declare optimal biologic dose for pivotal FORTIFI-HN01 study in Q1 2026.